van der Mijn, J.C., Panka, D.J., Geissler, A.K., Verheul, H.M. and Mier, J.W. (2016) Novel Drugs That Target the Metabolic Reprogramming in Renal Cell Cancer. Cancer & Metabolism, 4, 14.

has been cited by the following article:

• TITLE: Pazopanib Induced Hand-Foot Syndrome in a Patient Previously Treated with Sunitinib: A Possible Cumulative Skin Toxicity?

  AUTHORS: Emanuele Cozzani, Sanja Javor, Stefano Ottoboni, Aurora Parodi

  KEYWORDS: Hand-Foot Syndrome, Pazopanib, Sunitinib, Tyrosine-Kinase Inhibitors, Cumulative Toxicity 1.

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.7 No.8, August 30, 2016

  ABSTRACT: Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia, is a skin toxicity that could be observed during target therapies such as with tyrosine-kinase inhibitors (TKI). It usually develops within the first 2 - 4 weeks of drug administration. We present a case of HFS induced by Pazopanib after 2 months of treatment, in patients previously treated with Sunitinib, suggesting a possible cumulative toxicity of two drugs. The clinical and therapeutic management of skin adverse reactions during TKI therapy usually requires 25% dose reduction and adequate local treatment. It is important for the clinicians to recognize clinical signs and symptoms of such skin toxicities. Attention should be paid especially when two or more drugs from the same class are used in combined treatment.